Latest Articles
- The ENHANCE trial (July 2008)
Does ezetimibe still have a role? Comments on our article in the July 2008 issue describing the surprising results of an important trial.
- Biochemical markers of bone turnover: Useful but underused
Markers tell us the risk of fracture and are useful in patient management. But will insurance pay for testing?
- Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome
As we get heavier, our livers get fattier. Despite an explosion of research on nonalcoholic fatty liver disease and gains in understanding its epidemiology and pathogenesis, a number of issues remain unresolved, including how to treat it.
- Preventing renal disease progression: Can complete renin-angiotensin- aldosterone blockade work?
In view of the risks of complete blockade of the renin-angiotensin- aldosterone pathway, more data from clinical trials are needed before the general medical community widely applies this strategy to prevent progressive chronic kidney disease.